| 5.77 -0.02 (-0.35%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.43  |
1-year : | 9.95 |
| Resists | First : | 7.22 |
Second : | 8.52 |
| Pivot price | 5.62  |
|||
| Supports | First : | 5.11 | Second : | 4.25 |
| MAs | MA(5) : | 5.72 |
MA(20) : | 5.69 |
| MA(100) : | 6.06 |
MA(250) : | 3.8 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 59.6 |
D(3) : | 55.4 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 9.75 | Low : | 1.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NUVB ] has closed below upper band by 30.7%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.05 - 6.08 | 6.08 - 6.11 |
| Low: | 5.64 - 5.67 | 5.67 - 5.7 |
| Close: | 5.72 - 5.77 | 5.77 - 5.81 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Fri, 13 Feb 2026
Nuvation Bio Inc. (NYSE:NUVB) Is Expected To Breakeven In The Near Future - 富途牛牛
Tue, 10 Feb 2026
Forecasting The Future: 9 Analyst Projections For Nuvation Bio - Benzinga
Mon, 09 Feb 2026
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma - Business Wire
Fri, 06 Feb 2026
Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring 111.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Mon, 02 Feb 2026
Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy (NYSE:NUVB) - Seeking Alpha
Fri, 30 Jan 2026
Turist Financial Remains a Buy on Nuvation Bio (NUVB) - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 342 (M) |
| Held by Insiders | 2.3159e+008 (%) |
| Held by Institutions | 19 (%) |
| Shares Short | 45,980 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.3155e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -430.2 % |
| Return on Assets (ttm) | -24.9 % |
| Return on Equity (ttm) | -52.5 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 454.64 |
| Sales Per Share | 1.72581e+007 |
| EBITDA (p.s.) | 9.36129e+006 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -190 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 9.41 |
| Dividend | 0 |
| Forward Dividend | 4.795e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|